– USA, NY – Immunic, Inc. (Nasdaq: IMUX) today announced the appointment of Dr. Rick Rudick (M.D.) to its Board of Directors, effective April 26, 2023, bringing decades of experience in the clinic, academia, and industry.
“We are very grateful to have Rick join us. Rick has an extraordinary background spanning decades as a clinical expert in multiple sclerosis, clinical trialist who has overseen multiple successful pivotal studies, innovator, and pharmaceutical executive. He has published extensively and has been an active participant and leader in developing the treatment landscape for multiple sclerosis. We look forward to working with him to leverage his extensive knowledge, experience, and relationships, particularly concerning our ongoing development of vidofludimus calcium in multiple sclerosis, as well as our earlier programs,” said Board Chairman, Dr. Duane Nash.
The company also announced that Dr. Vincent Ossipow will step down from the Board, effective June 28, 2023.
About Dr. Richard Rudick
Dr. Rick Rudick is a Fellow of the American Academy of Neurology and served on the faculty of the Cleveland Clinic Foundation until 2014. While at the Cleveland Clinic, he was Director of the Mellen Center for Multiple Sclerosis Treatment and Research, Inaugural Chief Clinical Research Officer, Vice-Chair of the Cleveland Clinic Neuroscience Institute, and Co-Director of the city-wide Cleveland Clinical and Translational Science Collaborative. Between 2014 and 2020, Dr. Rudick served at Biogen as Director of the Value-Based Medicine Innovation Hub and Director of the Medical Evidence, Research, and Innovation Unit. He has authored over 250 peer-reviewed publications in the neurology space, was Chair of the National Multiple Sclerosis Society Research Program Advisory Committee, and was a member of the Advisory Council to the National Center for Research Resources and the Director’s Council of Councils at the National Institutes of Health.
Dr. Rudick earned his medical degree from Case Western Reserve University School of Medicine and completed clinical and research training at the University of Rochester.
About Immunic, Inc.
Immunic, Inc. is a biotechnology company developing a clinical pipeline of orally administered, small-molecule therapies for chronic inflammatory and autoimmune diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is in phase 3 clinical trials for the treatment of multiple sclerosis and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and moderate-to-severe ulcerative colitis, selectively inhibits activated immune cells and shows combined anti-inflammatory, anti-viral and neuroprotective effects. IMU-856 is targeted to restore intestinal barrier function and regenerate bowel epithelium, which would be applicable in numerous gastrointestinal diseases, such as celiac disease, where it is currently being evaluated in a clinical proof-of-concept trial.
For more information: https://imux.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
